We are live on
!
Find out more
KCM
Kynam Capital Management Portfolio holdings
AUM
$1.81B
1-Year Est. Return
192.15%
This Fund
S&P 500
This Quarter
Est. Return
+24.45%
1 Year Est. Return
+192.15%
3 Year Est. Return
+320.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.81B
AUM Growth
+$188M
(+12%)
Cap. Flow
+$7.54M
Cap. Flow
% of AUM
0.42%
Top 10 Holdings %
Top 10 Hldgs %
72.72%
Holding
43
New
4
Increased
12
Reduced
7
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viridian Therapeutics
VRDN
|
+$66.3M |
| 2 |
Legend Biotech
LEGN
|
+$38.4M |
| 3 |
Relay Therapeutics
RLAY
|
+$27.2M |
| 4 |
CytomX Therapeutics
CTMX
|
+$25.5M |
| 5 |
Summit Therapeutics
SMMT
|
+$21.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KALV
KalVista Pharmaceuticals
KALV
|
+$36.7M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$33.2M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$28.6M |
| 4 |
Beam Therapeutics
BEAM
|
+$25.4M |
| 5 |
Vera Therapeutics
VERA
|
+$18.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alector
ALEC
$275M
| $7.66M | 0.42% |
3,808,494
+1,808,494
| +90% | +$3.88M |
|
|
PBLS
27
Parabilis Medicines Inc
PBLS
$4.99B
| $6.84M | 0.38% |
+250,000
| New | +$6.91M |
|
28
Caribou Biosciences
CRBU
$168M
| $4.41M | 0.24% |
2,503,302
| – | – |
|
29
ProQR Therapeutics
PRQR
$292M
| $2.91M | 0.16% |
1,566,317
| – | – |
|
30
Candel Therapeutics
CADL
$978M
| $996K | 0.06% |
96,741
-103,259
| -52% | -$780K |
|
31
enGene Therapeutics
ENGN
$122M
| $792K | 0.04% |
457,855
-898,988
| -66% | -$3.67M |
|
32
Traws Pharma
TRAW
$8.45M
| $71.2K | ﹤0.01% |
+84,400
| New | +$116K |
|
|
APLS
33
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-825,000
| Closed | -$33.2M |
|
34
Biohaven
BHVN
$2.37B
| – | – |
-702,884
| Closed | -$5.95M |
|
35
Design Therapeutics
DSGN
$947M
| – | – |
-784,606
| Closed | -$8.35M |
|
|
KALV
36
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-1,820,954
| Closed | -$36.7M |
|
37
PUT
Revolution Medicines
RVMD
$45B
| – | – |
-207,500
| Closed | -$20.2M |
|
|
SLNO
38
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-560,000
| Closed | -$18.7M |
|
39
CALL
Travere Therapeutics
TVTX
$6.15B
| – | – |
-800,000
| Closed | -$23.8M |
|
|
40
PUT
Travere Therapeutics
TVTX
$6.15B
| – | – |
-54,900
| Closed | -$1.63M |
|
41
Wave Life Sciences
WVE
$958M
| – | – |
-965,193
| Closed | -$7M |
|
|
CLYM
42
Climb Bio
CLYM
$891M
| – | – |
-1,003,341
| Closed | -$6.87M |
|
|
EVMN
43
Evommune Inc
EVMN
$445M
| – | – |
-625,496
| Closed | -$14.4M |
|
Similar funds
AF
RP
LPT
SFG
GA
CCS
PPW
OPCM
Kynam Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Kynam Capital Management held 43 positions worth $1.81B, up 12% from $1.62B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Kynam Capital Management's Q2 2026 filing shows 4 new, 12 increased, 7 reduced and 11 closed positions. Its largest new stake was Summit Therapeutics: 1,200,000 shares worth $17.5M. The largest sale was KalVista Pharmaceuticals, an estimated $36.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.
- Kynam Capital Management's largest Q2 2026 buy was Summit Therapeutics: 1,200,000 shares worth $17.5M.
- Kynam Capital Management added most to Viridian Therapeutics in Q2 2026, an estimated $66.3M increase.
- Kynam Capital Management's biggest Q2 2026 reduction was BioCryst Pharmaceuticals, cutting an estimated $28.6M.
- Kynam Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $36.7M.
- Kynam Capital Management's ten largest holdings make up 73% of its $1.81B portfolio in Q2 2026.
- Kynam Capital Management opened 4 new positions and closed 11 in Q2 2026.
- Kynam Capital Management's portfolio value rose 12% quarter-over-quarter to $1.81B.
Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.